Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein UCP2
OwnerFrederic Bouillaud, Daniel Ricquier +1inventors
InventorsFrederic Bouillaud, Daniel Ricquier, Eduardo Rial Zueco
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a compound of the retinoid type particularly retinoid acid for the preparation of a medicament capable of modulating in vivo the decoupling activity of decoupling proteins. These compounds can be used conveniently for the treatment of diseases associated to an increase or reduction of the activity of decoupling proteins. According to a preferred embodiment, the retinoid acid will be used for the treatment of disease associate to a reduction of the decoupling activity of the protein UCP2 such as for example obesity.
Claims24
Use of a retinoid-type compound for the preparation of a medicament for increasing the uncoupling activity of UCP2 proteins.
A method of treatment for increasing the uncoupling activity of UCP2 proteins in mammals, the method comprising administering an effective amount of a retinoid-type compound to an individual in the need of said treatment.
A formulation for increasing the uncoupling activity of UCP2 proteins, the formulation comprising an effective amount of a retinoid-type compound.
Dependencies are inferred from the claim text.